{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-050659","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.057665+00:00","generated_at":"2026-06-05T09:03:18.231053+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Absci prices $75.2M public offering of 16.7M shares at $4.50; net proceeds $70.2M","bullets":["Offering of 16.7M shares at $4.50/share; gross proceeds ~$75.2M; net proceeds ~$70.2M.","Underwriters granted 30-day option to purchase up to 2.505M additional shares.","Net proceeds to fund internal asset programs, Integrated Drug Creation platform, AI/wet-lab tech, and working capital.","Cash runway extended into first half of 2027; offering expected to close March 1, 2024.","Joint book-running managers: Morgan Stanley and TD Cowen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-050659","json":"https://secwatch.observer/filing/0001193125-24-050659.json","markdown":"https://secwatch.observer/filing/0001193125-24-050659.md","text":"https://secwatch.observer/filing/0001193125-24-050659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000119312524050659/0001193125-24-050659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000119312524050659/d768554d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:03:18.231053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"178d3eab1e348160f9864713355e9c4de7c02350","claim":"Absci Corp entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Cowen & Company, LLC valued at public offering price of $4.50 per share (effective 2024-02-27).","evidence_excerpt":"On February 27, 2024, Absci Corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Cowen & Company, LLC (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 16,700,000 shares (the “ Underwritten Shares ”) of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000119312524050659/0001193125-24-050659-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC and Cowen & Company, LLC"},{"label":"Value","value":"public offering price of $4.50 per share"},{"label":"Effective","value":"2024-02-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}